Prostate cancer has long since been recognised as being hormonally driven via androgen receptor signalling. Abiraterone acetate (AA) is a rationally designed CYP17 inhibitor that blocks the conversion of androgens from non-gonadal precursors effectively, thus reducing testosterone to undetectable levels. AA has recently been proved to extend survival for men with metastatic castration-resistant prostate cancer who have progressive disease after first-line chemotherapy treatment. In addition, it is currently being tested in a Phase III trial in the pre-chemotherapy setting. This paper will review the preclinical discovery and clinical development of AA and will outline the strategy of parallel translational research.
Pezaro CJ, Mukherji D, De Bono JS. Are you the author?
Drug Development Unit and Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK; The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
Reference: Drug Discov Today. 2011 Dec 19. Epub ahead of print.
UroToday.com Prostate Cancer Section